CORT Corcept Therapeutics Incorporated

10.33
-0.03  -0%
Previous Close 10.36
Open 10.38
Price To Book 4.15
Market Cap 1,186,490,454
Shares 114,858,708
Volume 526,127
Short Ratio
Av. Daily Volume 707,699

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved February 17, 2012.
Corlux - Korlym
Cushing's Syndrome
Phase 1/2 presented at ASCO June 3, 2019.
Relacorilant plus Abraxane
Solid tumors - cancer
Phase 3 commencement of enrolment announced November 19, 2018.
Relacorilant
Cushing’s syndrome
Phase 2 trial ongoing - noted May 9, 2019.
Relacorilant plus Abraxane
Ovarian cancer
Phase 2 trial to be initiated 2H 2019.
CORT118335
Nonalcoholic steatohepatitis (NASH)
Phase 1/2 dosing ongoing - May 9, 2019.
CORT125281 plus Xtandi
Castration-resistant prostate cancer (CRPC)
Phase 1b trial has been initiated.
CORT118335
Prevention of antipsychotic-induced weight gain
Phase 2 trial to be initiated 2H 2019.
CORT118335
Reversal of antipsychotic-induced Weight Gain (AIWG)

Latest News

  1. Corcept Therapeutics Incorporated (NASDAQ:CORT): Poised For Long Term Success?
  2. Corcept (CORT) Down 11.3% Since Last Earnings Report: Can It Rebound?
  3. The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace
  4. Is Corcept Therapeutics Incorporated's (NASDAQ:CORT) P/E Ratio Really That Good?
  5. Corcept Therapeutics to Present Data from Phase 1/2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Solid Tumors at the American Society of Clinical Oncology Annual Meeting
  6. Lawsuit for Investors in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) announced by Shareholders Foundation
  7. Edited Transcript of CORT earnings conference call or presentation 9-May-19 9:00pm GMT
  8. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Corcept, Mobile TeleSystems, Healthcare Services, and American Renal and Encourages Investors to Contact the Firm
  9. CRBP, NIO & CORT Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Class Action
  10. DEADLINE MONDAY REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  11. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CORT, HCSG, BA and NOK
  12. DEADLINE TODAY: Rosen Law Firm Reminds Corcept Therapeutics Incorporated Investors of Important May 13th Deadline in Securities Class Action Lawsuit - CORT
  13. INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In NIO, CORT, HCSG or FCHS To Contact The Firm
  14. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CORT, FSNN and BSX
  15. 3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  16. CLASS ACTION UPDATE for CORT, FSNN and MWA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  17. DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  18. Corcept Therapeutics Incorporated (CORT) Q1 2019 Earnings Call Transcript
  19. Corcept Therapeutics (CORT) Q1 Earnings Top Estimates